Teva Pharmaceutical Industries Limited

NYSE:TEVA

Drug Manufacturers - Specialty & Generic

Healthcare
$42.23 -3.35%

-$1.09 today

Market cap
$49.28B
Beta
0.85
P/E (TTM)
23.1
EPS (TTM)
$1.36
52W Low $14.99High $37.35

Volume 8.86M

Average 6.22M

TEVA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Teva Pharmaceutical Industries LimitedNYSE: TEVA

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $250M rose 2.5% year over year, ahead of the -0.7% change in trailing-twelve-month research & development. Sequentially, it rose 12.6% from the prior quarter. Over 3 fiscal years it compounded at +6.5% a year.

Context

  • Research & development amounted to 5.9% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +2.5% holds above the trailing-twelve-month pace of -0.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$250M+12.6% QoQ
Last fiscal yearDec 2025
$1.01B-4.0% YoY
LTMJun 2026
$995M-0.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.5%——
1 year-4.0%——
3-year CAGR+6.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
1.01B USD
Year-over-year change
-4.0%
4-year CAGR
-1.9%

Research & Development vs competitors

How TEVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.7% is the 3rd highest of 5, against a peer median of -3.5%.
  • Research & development amounts to 5.7% of revenue for TEVA, versus a peer median of 6.9%.
TEVA Competitors
Research & Development for TEVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹22.73B INR-13.8%+9.3%6.9%
VTRSViatris Inc.LTM Jun 2026$1.02B USD+20.8%+13.4%6.9%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$995M USD-0.7%+6.5%5.7%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$177.66M USD-15.0%-3.7%5.7%
ALVOAlvotechLTM Mar 2026$170.53M USD+6.8%+0.7%30.5%
Peer median (excluding TEVA) —-3.5%+5.0%6.9%

Competitors are the stored peer set for TEVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue15.88B14.93B15.85B16.54B17.26B
Cost of Revenue8.28B7.95B8.2B8.48B8.32B
Gross Profit7.59B6.97B7.65B8.06B8.94B
Gross Margin47.8%46.7%48.2%48.7%51.8%
Research & Development1.09B838M953M1.06B1.01B
Selling, General & Admin3.53B3.45B3.5B3.7B3.97B
Operating Expenses5.88B9.17B7.21B8.37B6.78B
Depreciation & Amortization1.33B1.31B1.15B1.06B1B
EBITDA4.41B(925M)1.56B4.43B3.14B
EBITDA Margin27.8%-6.2%9.8%26.8%18.2%
Operating Income1.72B(2.2B)433M(303M)2.16B
Operating Margin10.8%-14.7%2.7%-1.8%12.5%
Interest Income0068M00
Interest Expense891M930M1.03B941M916M
Other Income / Expenses(1.05B)(945M)(1.06B)(980M)(919M)
Income Before Tax667M(3.14B)(622M)(1.28B)1.24B
Pre-Tax Margin4.2%-21.1%-3.9%-7.8%7.2%
Income Tax Expense211M(643M)(7M)676M(180M)
Net Income417M(2.45B)(559M)(1.64B)1.41B
Net Margin2.6%-16.4%-3.5%-9.9%8.2%
EPS (Basic)0.38(2.20)(0.50)(1.45)1.23
EPS (Diluted)0.38(2.20)(0.50)(1.45)1.20
Weighted Avg Shares1.1B1.11B1.12B1.13B1.15B
Weighted Avg Shares (Diluted)1.11B1.11B1.12B1.13B1.17B

Teva Pharmaceutical Industries Limited

NYSE:TEVA

Intrinsic Alpha fair value

Locked

Current Price

$42.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.